New Data in HR+/HER2- Metastatic Breast Cancer Shows Progression-Free Survival Benefit of Trodelvy

 Progression-Free Survival Efficacy of Trodelvy Consistent with That Observed in the TROPiCS-02 Intention-to-Treat Population --

-- Results Presented at ESMO 2022 Highlight Trodelvy as a Potential Treatment Option in HR+/HER2-Low and IHC0 Status Metastatic Breast Cancer --

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post hoc subgroup analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapies (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies. The analysis examined progression-free survival (PFS) in the intention-to-treat population by HER2-immunohistochemistry (IHC) status, and the results demonstrated that Trodelvy improved median PFS vs. TPC in both HER2-low (IHC1+ and IHC2+/ISH-negative) and IHC0 groups.

Summary of results:

	HER2-low		IHC0		ITT
	Trodelvy arm (n=149)	TPC arm (n=134)	Trodelvy arm (n=101)	TPC arm (n=116)	Trodelvy arm (n=272)	TPC arm (n=271)
Median PFS (months)	6.4	4.2	5.0	3.4	5.5	4.0
Hazard ratio (95% confidence interval) p-value	0.58 (0.42-0.79)		0.72 (0.51-1.00)		0.66 (0.53 – 0.83) p=0.0003

Detailed findings will be presented at a mini-oral session (Abstract #1362) during the European Society for Medical Oncology (ESMO) Congress 2022 in the Évry Auditorium, Paris Expo Porte de Versailles, on September 10.

https://finance.yahoo.com/news/tropics-02-data-hr-her2-220500157.html